Results 91 to 100 of about 7,321 (205)

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 [PDF]

, 2015
We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrugexperienced subjects were sequenced and the HIV-1-env gene cloned into ...
Valdez, H, Ceccherini-Silberstein, Francesca, V. Svicher, Harrigan, R., Artese, A., D. Chapman, J. Martinez-Picado, Lewis, M, Balestra E, Clotet, Bonaventura, B. Clotet, Costa G, ALTERI, CLAUDIA, Svicher V, C. Alteri, Alteri C, Martinez Picado J, S. Alcaro, Chapman, D., Swenson, L., Puertas, M.C., Costa, G., Ceccherini Silberstein F., Alcaro, S., Swenson, L, Artese A, BALESTRA, EMANUELA, Saccomandi, P., Ceccherini-Silberstein, F, Clotet, B., M. Surdo, E. Balestra, Martinez Picado, J, Clotet, B, Ceccherini-Silberstein, F., Lewis M, ARTESE, ANNA, G. Costa, SACCOMANDI, PATRIZIA, Artese, A, Saccomandi, P, Costa, G, Svicher, V, Martinez-Picado, J., Chapman, D, Alteri, C., H. Valdez, Clotet B, Parrotta, L, Balestra, E., Balestra, E, Perno CF, Alteri, C, L. Swenson, Parrotta L, A. Artese, Saccomandi P, Surdo, M., Svicher, V., P. Saccomandi, Surdo, M, Ceccherini-Silberstein F, Puertas, MC, F. Ceccherini-Silberstein, M.C. Puertas, AQUARO, STEFANO, Perno, Cf, Alcaro S, Perno, C.F., PERNO, CARLO FEDERICO, Parrotta, L., Martinez Picado, Francisco Javier, S. Aquaro, Harrigan, R, Aquaro, S, M. Lewis, Lewis, M., Alcaro, S, CECCHERINI SILBERSTEIN, FRANCESCA, Swenson L, Martinez-Picado J, L. Parrotta, Chapman D, Surdo M, SVICHER, VALENTINA, Aquaro, S., Aquaro S, Martinez-Picado, J, C.F. Perno, Puertas MC, R. Harrigan, Valdez H, Harrigan R, Valdez, H.   +93 more
core   +1 more source

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.

PLoS ONE, 2011
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and
C Preston Neff, Theresa Kurisu, Thomas Ndolo, Kami Fox, Ramesh Akkina   +4 more
doaj   +1 more source

Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques

, 2010
Single-dose nevirapine (NVP) is effective in reducing mother-to-child transmission (MTCT) of HIV; however, the subsequent development of drug resistance is problematic.
Mark A. Winters, Angela D. M. Kashuba, Nancy S. Shulman, Kashuba, A. D. M., Van Rompay, K. K. A., Winters, M. A., Mark Holodniy, Shulman, N. S., Koen K. A. Van Rompay, Holodniy, M.   +9 more
core   +1 more source

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

PLoS ONE, 2014
ObjectivesRegimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens ...
Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper   +5 more
doaj   +1 more source

Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women

, 2009
To compare single- and multiple-dose maraviroc exposures in cervicovaginal fluid (CVF) and vaginal tissue (VT) with blood plasma (BP) and quantify maraviroc protein binding in ...
Andrews, Emma, Worsley, Jochen, Patterson, Kristine B, Werner, Rebecca E, Dumond, Julie B, Pecha, Allison L, Damle, Bharat, Kashuba, Angela D M, Tressler, Randall   +8 more
core   +1 more source

Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence

, 2013
Objectives: Resistance of HIV-1 to CCR5 antagonists can occur without coreceptor switching by mutations in envelope glycoproteins that enable virus entry using the inhibitor-bound form of CCR5.
Izopet, J., Coassin, L., Cazabat, M., Saliou, A., Requena, M., Massip, P., Delobel, P., Marchou, B., Loiseau, C., Raymond, S.   +9 more
core   +1 more source

Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc

, 2016
CCR5 antagonists are among the most advanced approaches in HIV therapy and may also be relevant to treatment of graft-versus-host disease and Staphylococcus aureus infection.
Julia Gavrilyuk (1396897), Shigehiro Asano (1331397), Carlos F. Barbas (19478), Dennis R. Burton (1846123)   +3 more
core   +1 more source

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects - Fig 3

, 2019
Steady-state geometric mean Maraviroc concentration-time profile (log-scale) for subjects receiving Maraviroc alone (squares and solid line) and Maraviroc plus Rifabutin (circles and dashed line)(A). Steady-state maraviroc concentration-time profile (log-
E. Sabri (7542692), C. la Porte (7542683), G. Zhang (808141), M. Ghannad (7542677), R. Mallick (5874875), M. Dennehy (7542680), S. Kanji (3407216), D. W. Cameron (7542695), I. Seguin (7542686), D. Tardiff (7542689)   +9 more
core   +1 more source

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

PLoS Pathogens, 2016
Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remains ...
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae-Wook Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth   +18 more
doaj   +1 more source

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

, 2017
Background Despite the recent advances in the understanding of natalizumab (NTZ) related progressive multifocal leukoencephalopathy (PML) and its associated immune reconstitution inflammatory syndrome (PML-IRIS), the therapeutic options are still under ...
Alessandra Lugaresi, Capobianco M., Gerevini, Simonetta, Simonetta Gerevini, Capra R., Ruggero Capra, Lucia Moiola, Mancinelli, Chiara R., Cristina Scarpazza, Imberti, Luisa, Lugaresi A., Naldi P., Scarpazza C., Paola Naldi, Luca Prosperini, Prosperini L., Moiola, Lucia, Prosperini, Luca, Naldi, Paola, Gerevini S., Mancinelli C. R., De Rossi, Nicola, Chiara R. Mancinelli, Nicola De Rossi, Capobianco, Marco, Moiola L., De Rossi N., Marco Capobianco, LUGARESI, ALESSANDRA, Capra, Ruggero, Scarpazza, Cristina, Imberti L., Luisa Imberti   +32 more
core   +1 more source